Article
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
International journal of cancer - 15 Apr 2022
Zhao Yang, Li Shuyan, Yang Xi, Chu Li, Wang Shengping, Tong Tong, Chu Xiao, Yu Fan, Zeng Ya, Guo Tiantian, Zhou Yue, Zou Liqing, Li Yida, Ni Jianjiao, Zhu Zhengfei
Abstract excerpt
Osimertinib, as a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed more potent efficacy against brain metastasis (BM) in untreated EGFR-mutant nonsmall cell lung cancer (NSCLC) in the FLAURA study. However, the overall survival (OS) benefit of osimertinib and clinical value of cranial local therapy (CLT) in these patients remain undetermined. Here we conducted a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.